Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C

[1]  N. Hayashi,et al.  Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  A. Bruchfeld,et al.  High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C , 2005, Hepatology.

[3]  N. Hayashi,et al.  The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  P. Portincasa,et al.  Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin‐induced hemolysis in hepatitis C , 2004, Hepatology.

[5]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[6]  P. Portincasa,et al.  Low membrane protein sulfhydrils but not glucose‐6‐phosphate dehydrogenase deficiency predict ribavirin‐induced hemolysis , 2004 .

[7]  T. Murakami,et al.  Dosage Adjustment of Ribavirin Based on Renal Function in Japanese Patients with Chronic Hepatitis C , 2004, Therapeutic drug monitoring.

[8]  A. Bruchfeld,et al.  Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin‐induced anaemia , 2004, Journal of viral hepatitis.

[9]  L. Rostaing,et al.  Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  Valeer J Desmet,et al.  Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. , 2003, Journal of hepatology.

[11]  A. Bruchfeld,et al.  Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic Analysis , 2002, Therapeutic drug monitoring.

[12]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[13]  K. Eguchi,et al.  Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C , 2002, Cancer.

[14]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[15]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[16]  M. Vos,et al.  Factors influencing ribavirin-induced hemolysis. , 2001, Journal of hepatology.

[17]  G. Hajian,et al.  Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C , 2000, Therapeutic drug monitoring.

[18]  G. Fattovich,et al.  Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage , 2000, Hepatology.

[19]  F. Negro,et al.  Severe anemia following combined α-interferon/ribavirin therapy of chronic hepatitis C , 1998 .

[20]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[21]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[22]  N. Hayashi,et al.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C , 1998, Hepatology.

[23]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[24]  F. Negro,et al.  Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C. , 1998, Journal of hepatology.

[25]  G. Davis,et al.  Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial , 1997, Hepatology.

[26]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[27]  N. Hayashi,et al.  Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. , 1995, Journal of hepatology.

[28]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.